Totalis Biologics began in 1922 as a private biomedical research consortium under the name Aurum Vita Initiative, originally headquartered near Lake Geneva. The organization brought together early pioneers in cellular longevity, mitochondrial restoration, and metabolic entropy modeling — decades ahead of mainstream scientific acceptance. Though largely unrecognized in public channels, Aurum Vita quietly funded some of the earliest research into cryogenic suspension, telomerase reactivation, and tissue matrix recalibration.

In 1965, under the stewardship of enigmatic founder Dr. Adrien Vallis, the consortium reorganized as Totalis. Vallis, a polymath trained in both theoretical physics and ancient ethnobotany, spearheaded the group’s foundational premise: death is not a biological certainty, but a systemic failure that can be optimized, delayed, and ultimately disrupted.

Dr. Vallis’ writings (archived but unpublished) contain references to early Khemic scrollwork and the Corpus Hemetica Somatum, a rumored text often dismissed by academia. Vallis disappeared from public records in 1981, but internal memos suggest he remains "active in offsite advisory capacity."

Today, Totalis operates globally through decentralized longevity labs, quantum metabolic simulators, and transdermal neuroplasmic delivery research cells. The Totalis 365 System is our flagship integration — a daily protocol of biological harmonization, psychosomatic clarity, and topical cellular recoding.

"We do not defy death. We reprogram it." — Dr. A. Vallis